研究单位：[1]Chinese PLA General Hospital[2]Beijing Tongren Hospital, Capital Medical University,Beijing,Beijing,China[3]Peking Union Medical College Hospital,Beijing,Beijing,China[4]Peking University Cancer Hospital,Beijing,Beijing,China[5]Zhujiang Hospital of Southern Medical University,Guangzhou,Guangdong,China[6]Sun Yat-Sen University Cancer Hospital,Guangzhou,Guangzhou,China[7]Tongji Hospital, Tongji Medical College of HUST,Wuhan,Hubei,China[8]Xiehe Hospital, Tongji Medical College of HUST,Wuhan,Hubei,China[9]Tongji Hospital of Tongji University,Shanghai,Shanghai,China[10]West China Hospital of Sichuan University,Chengdu,Sichuan,China[11]The First Affiliated Hospital of Soochow University,Suzhou,Suzhou,China[12]Tianjin Medical University Cancer Institute and Hospital,Tianjin,Tianjin,China[13]The First Affiliated Hospital of Zhejiang University,Hangzhou,Zhejiang,China[14]Biotherapeutic Department, Chinese PLA General Hospital,Beijing,China
The previous research suggests that the low expression of NOXA protein may be an important biomarker for the treatment of drug resistance of chimeric antigen receptor-T (CAR-T) cells. Up regulating the expression of NOXA through histone deacetylase inhibitor (HDACi) can improve drug resistance and significantly improve the therapeutic effect of CAR-T cells. This study will enroll approximately 120 subjects with recurrent or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL). Those with high expression of NOXA will receive conventional CAR-T treatment (without chidamide bridging), and those with low expression of NOXA will be randomly assigned 1:1 to those without or containing chidamide bridging. The purpose of this study was to evaluate the clinical response and safety of chidamide bridging.
